Headquartered in Boston, MA Fiscal year ends December NASDAQ: KRTX karunatx.com
Karuna Therapeutics Inc is a pioneering biopharmaceutical company based in Boston, Massachusetts, dedicated to developing innovative medicines for psychiatric and neurological conditions. Its flagship product, KarXT, is an oral treatment aimed at managing acute psychosis in schizophrenia patients, along with addressing cognitive symptoms and dementia-related psychosis, including Alzheimer's disease. The company is also exploring other drug candidates targeting muscarinic receptors for various mental health disorders. Karuna Therapeutics boasts strategic partnerships with notable entities like Eli Lilly and Zai Lab, emphasizing its commitment to advancing mental health care.
Another acquisition for Bristol Myers, another acquisition offer from Nano Dimension, and Apple's Watch woes.
The last trading day before the Christmas holiday has stocks headed for a mixed opening following a good, not great, inflation report.
Karuna Therapeutics Inc is a pioneering biopharmaceutical company based in Boston, Massachusetts, dedicated to developing innovative medicines for psychiatric and neurological conditions.
The Wall Street consensus 12-month price target for KRTX is $324.17.
